NAMZARIC now available in prescription in U.S.
This includes all four dosage strengths of the medication, which are once-daily, fixed-dose extended-release capsules combined with memantine hydrochloride and donepezil hydrochloride developed to treat moderate to severe Alzheimer’s disease for patients who are currently taking 10 mg of donepezil hydrochloride once daily.
"We are excited that with the new available dosage strengths patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg) can now start combination therapy directly with NAMZARIC,” Allergen CMO Dr. Gavin Corcoran said. “NAMZARIC offers these patients the benefits of combining two products that each work differently to treat moderate to severe Alzheimer's disease, without increasing the number of pills a patient and their caregiver need to administer each day. This launch reinforces Allergan's commitment to development of treatments for Alzheimer's Disease and other neurological disorders."
Clinical trials have proven that a combination therapy involving Namenda XR and an AChEl such as Aricept for patients who have been diagnosed with moderate to severe Alzheimer’s, which is approximately three out of every four, have shown a significantly higher improvement in cognitive and global functions compared to AChEl by itself.